FrancophonIA/ELRC3.0 huggingface dataset:
English: The active substance in Keppra, levetiracetam, is an anti-epileptic medicine.
Estonian: Keppra toimeaine levetiratsetaam on epilepsiaravim.
English: The daily dose can be increased up to 1,500 mg twice a day.
Estonian: Ööpäevast annust tohib suurendada annuseni 1500 mg kaks korda ööpäevas.
English: The dose can be further increased at two-week intervals according to the patient's response, to a maximum dose of 1,500 mg twice a day.
Estonian: Olenevalt patsiendi ravivastusest tohib annust 2-nädalase intervalliga suurendada kuni maksimaalse annuseni 1500 mg kaks korda ööpäevas.
English: Keppra has also been studied as an add-on treatment:
Estonian: Kepprat uuriti ka lisaravimina järgmistel juhtudel:
English: Keppra can be given as an infusion using the same doses at the same frequency when using the tablets or the oral solution is not possible.
Estonian: Kui tablette või suukaudset lahust ei saa kasutada, tohib Kepprat manustada infusiooni abil, kasutades sama sagedusega samu annuseid.
English: As an add-on treatment, Keppra was more effective than placebo:
Estonian: Lisaravimina oli Keppra platseebost efektiivsem järgmistel juhtudel:
English: What is Keppra used for?
Estonian: Milleks Kepprat kasutatakse?
English: In these studies, Keppra at doses of 1,000, 2,000 or 3,000 mg per day, was compared with placebo (a dummy treatment) over 12 to 14 weeks.
Estonian: • Partsiaalsed epilepsiaepisoodid; Kepprat uuriti kolmes põhiuuringus, milles osales kokku 904 vähemalt 16-aastast patsienti ja milles võrreldi platseeboga (näiv ravim) 12-14 nädala jooksul Keppra annuseid 1000, 2000 või 3000 mg ööpäevas.
English: How is Keppra used?
Estonian: Kuidas Kepprat kasutatakse?
English: How has Keppra been studied?
Estonian: Kuidas Kepprat uuriti?
English: This summary was last updated in 02-2015.
Estonian: Kokkuvõtte viimane uuendus: 02-2015.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Tasermity on 26 February 2015.
Estonian: Euroopa Komisjon andis Tasermity müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 26. veebruaril 2015.
English: What measures are being taken to ensure the safe and effective use of Tasermity?
Estonian: Mis meetmed võetakse, et tagada Tasermity ohutu ja efektiivne kasutamine?
English: The full EPAR for Tasermity can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Tasermity kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: A risk management plan has been developed to ensure that Tasermity is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Tasermity võimalikult ohutu kasutamine.
English: This medicine is the same as Renagel, which is already authorised in the European Union (EU).
Estonian: See ravim on samane Renageliga, millel juba on Euroopa Liidus müügiluba.
English: What is Tasermity and what is it used for?
Estonian: Mis on Tasermity ja milleks seda kasutatakse?
English: Other information about Tasermity
Estonian: Muu teave Tasermity kohta
English: Tasermity must be taken with meals and patients should keep to their prescribed diets.
Estonian: Tasermityt tuleb manustada koos toiduga ja patsiendid peavad järgima neile määratud dieeti.
English: This helps to reduce the phosphate levels in the blood.
Estonian: See aitab vähendada vere fosfaadisisaldust.
English: Tasermity is available as tablets (800 mg).
Estonian: Tasermityt turustatakse tablettidena (800 mg).
English: The recommended starting dose of Tasermity is 1 or 2 tablets three times a day, depending on clinical need and the level of phosphate in the blood.
Estonian: Tasermity soovitatav algannus on 1 või 2 tabletti kolm korda ööpäevas, sõltuvalt kliinilisest vajadusest ja vere fosfaadisisaldusest.
English: The company that makes Renagel has agreed that its scientific data can be used for Tasermity (‘informed consent').
Estonian: Renageli tootja on andnud nõusoleku, et tema teaduslikke andmeid võib kasutada ka Tasermity toetuseks (teabel põhinev nõusolek).
English: It is not intended to provide practical advice on how to use Tasermity.
Estonian: Hindamisaruandes ei anta Tasermity kasutamise praktilisi nõuandeid.
English: This leads to phosphate accumulating in the body, which, in the long term, can cause complications affecting the heart and the bones.
Estonian: See põhjustab fosfaadi kogunemist organismi, mis võib pikema aja jooksul põhjustada südame- ja luutüsistusi.
English: Why is Tasermity approved?
Estonian: Miks Tasermity heaks kiideti?
English: The dose of Tasermity should be adjusted every two to three weeks to reach an acceptable level of phosphate in the blood, which should then be monitored regularly.
Estonian: Tasermity annust tuleb kohandada iga 2-3 nädala tagant, et saavutada vere vajalik fosfaadisisaldus, ning seda sisaldust tuleb edaspidi korrapäraselt kontrollida.
English: The most common side effects with Tasermity (which may affect more than 1 in 10 people) are nausea (feeling sick) and vomiting.
Estonian: Tasermity kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on iiveldus ja oksendamine.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Tasermity's benefits are greater than its risks for the treatment of hyperphosphataemia and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Tasermity kasulikkus hüperfosfateemia ravis on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: What are the risks associated with Tasermity?
Estonian: Mis riskid Tasermityga kaasnevad?
English: Studies have shown that Tasermity significantly reduces blood phosphate levels in patients with kidney disease undergoing dialysis.
Estonian: Uuringud tõendasid, et Tasermity vähendab oluliselt vere fosfaadisisaldust neeruhaigusega patsientidel, kes saavad dialüüsi.
English: Similar results with Tasermity were seen in another 8-week study involving 172 haemodialysis patients, while in a third longer-term study (over 44 weeks) Tasermity led to an average fall of 0.71 mmol/l.
Estonian: Tasermity kasutamisel täheldati sarnaseid tulemusi teises 8-nädalases uuringus, milles osales 172 hemodialüüsi saavat patsienti, ja kolmandas pikemaajalises uuringus (üle 44 nädala) vähendas Tasermity fosfaadisisaldust keskmiselt 0,71 mmol/l.
English: Tasermity should be used with other treatments such as calcium supplements and vitamin D to prevent the development of bone disease.
Estonian: Tasermityt peab kasutama koos muu raviga, näiteks koos kaltsiumipreparaatide ja D-vitamiiniga, et ennetada luuhaigusi.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Tasermity, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Tasermity omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: Patients with severe kidney disease cannot eliminate phosphate from their bodies.
Estonian: Rasket neeruhaigust põdevate patsientide organism ei suuda fosfaati väljutada.
English: For the full list of all side effects and restrictions with Tasermity, see the package leaflet.
Estonian: Tasermity kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: In a study of 84 patients undergoing haemodialysis, there was an average fall in phosphate levels of 0.65 mmol/l in patients taking Tasermity for 8 weeks, compared with a fall of 0.68 mmol/l in patients taking calcium acetate, another phosphate-lowering medicine.
Estonian: Uuringus, milles osales 84 hemodialüüsi saavat patsienti, vähenes Tasermityt 8 nädalat manustanud patsientidel fosfaadisisaldus keskmiselt 0,65 mmol/l võrreldes 0,68 mmol/l vähenemisega patsientidel, kes manustasid kaltsiumatsetaati, mis on samuti fosfaadisisaldust vähendav ravim.
English: How does Tasermity work?
Estonian: Kuidas Tasermity toimib?
English: It can be used in patients undergoing haemodialysis (using a blood filtration machine) or peritoneal dialysis (where fluid is pumped into the abdomen and an internal body membrane filters the blood).
Estonian: Seda tohib kasutada patsientidel, kes saavad hemodialüüsi (meetod, kus verd puhastab väline filterseade) või peritoneaaldialüüsi (meetod, kus vedelikku pumbatakse kõhtu ja verd filtreerib kõhukelme).
English: For practical information about using Tasermity, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Tasermity kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: The benefit of Tasermity has also been shown in a study of 143 patients undergoing peritoneal dialysis: patients receiving Tasermity in this study had similar falls in phosphate levels over 12 weeks as the patients receiving calcium acetate (0.52 and 0.58 mmol/l, respectively).
Estonian: Tasermity kasulikkust tõendati ka 143 peritoneaaldialüüsi saava patsiendiga uuringus: selles uuringus Tasermityt saanud patsientidel vähenes fosfaadisisaldus 12 nädala jooksul ligikaudu sama palju kui kaltsiumatsetaati saanud patsientidel (vastavalt 0,52 ja 0,58 mmol/l).
English: Tasermity contains the active substance sevelamer hydrochloride.
Estonian: Tasermity sisaldab toimeainena sevelameerhüdrokloriidi.
English: For more information about treatment with Tasermity, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Tasermityga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: When taken with meals, the sevelamer molecules in Tasermity attach in the gut to phosphate from food, preventing it from being absorbed into the body.
Estonian: Koos söögiga võetava Tasermity sevelameeri molekulid seonduvad sooles toidu fosfaatidega ja takistavad fosfaatide imendumist organismis.
English: Tasermity sevelamer hydrochloride
Estonian: Tasermity sevelameerhüdrokloriid
English: Tasermity is a medicine used to control hyperphosphataemia (high blood phosphate levels) in adult patients on dialysis (a blood clearance technique).
Estonian: Tasermity on ravim, mida kasutatakse hüperfosfateemia (vere liigse fosfaadisisalduse) kontrolliks dialüüsi (teatud verepuhastusmeetod) saavatel täiskasvanud patsientidel.
English: What benefits of Tasermity have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Tasermity kasulikkus?
English: The active substance in Tasermity, sevelamer hydrochloride, is a phosphate binder.
Estonian: Tasermity toimeaine sevelameerhüdrokloriid on fosfaate siduv aine.
English: This is a summary of the European public assessment report (EPAR) for Tasermity.
Estonian: See on ravimi Tasermity Euroopa avaliku hindamisaruande kokkuvõte.
English: Tasermity must not be used in people with hypophosphataemia (low blood phosphate levels) or with bowel obstruction (a blockage in the gut).
Estonian: Tasermityt ei tohi kasutada inimesed, kellel on hüpofosfateemia (vere väike fosfaadisisaldus) või sooleobstruktsioon (soolesulgus).
English: How is Tasermity used?
Estonian: Kuidas Tasermityt kasutatakse?
English: 2 to 4 GBq per vial at calibration date
Estonian: 2 kuni 4 GBq viaali kohta kalibreerimiskuupäeval
English: Vial (glass)
Estonian: Viaal (klaas)
English: 1.5 - 3.1 ml 1 vial
Estonian: 1,5 ml - 3,1 ml
English: Intravenous use
Estonian: Intravenoosne kasutamine
English: Pharmaceutical form Route of administration Packaging Content
Estonian: Ravimvorm Manustamistee Pakendi iseloomustus
English: Solution for injection.
Estonian: Ravimpreparaadi nimetus
English: Before you start Read these messages first
Estonian: Enne alustamist Loe kõigepealt neid teateid
English: Date of first authorisation: 11 March 2010 Date of latest renewal: 15 January 2015
Estonian: Müügiloa esmase väljastamise kuupäev: 11. märts 2010 Müügiloa viimase uuendamise kuupäev: 15. jaanuar 2015
English: Your doctor will discuss this with you.
Estonian: Arst arutab seda teiega.
English: Revolade may take 1 to 2 weeks to work.
Estonian: Revolade toime avaldumiseks võib kuluda 1 kuni 2 nädala.
English: • progressive, or
Estonian: • progresseeruv või
English: ... and for 2 hours after
Estonian: ... ja 2 tundi pärast
English: Revolade with food and drink
Estonian: Revolade koos toidu ja joogiga
English: Genotype 1/4/6
Estonian: Genotüüp 1/4/6
English: Other medicines and Revolade
Estonian: Muud ravimid ja Revolade
English: % patients achieving virologic response
Estonian: % patsientidest, kes saavutavad viroloogilise vastuse
English: Now you need to complete steps 11 to 13 to make sure the child receives all of the medicine.
Estonian: Nüüd tuleb läbi teha sammud 11 kuni 13, et laps saaks kogu ravimiannuse.
English: Make sure that
Estonian: Veenduge, et
English: Patients received study medication for up to 8 years (in EXTEND).
Estonian: Patsiendid said uuringuravimit kuni 8 aastat (EXTEND-is).
English: The majority of TEEs were non-serious and resolved by the end of the study.
Estonian: Enamus TEEst olid mittetõsised ja lahenesid uuringu lõppedes.
English: Method of administration (see section 6.6)
Estonian: Manustamisviis (vt lõik 6.6)
English: • Tell your doctor if you are pregnant, think you may be pregnant, or are planning to have a baby.
Estonian: • Teavitage arsti sellest, kui te olete rase, arvate end olevat rase või kavatsete last saada.
English: • lack of energy
Estonian: • energia puudus
English: Again fill the syringe, this time with 10 ml of drinking water.
Estonian: Täitke süstal uuesti, seekord 10 ml joogiveega.
English: Care should be taken when using Revolade if you are aged 65 years or above.
Estonian: Revolade kasutamisel on vajalik ettevaatus, kui olete 65-aastane või vanem.
English: Symptoms include:
Estonian: Sümptomid on:
English: HCV RNA Genotype Genotype 2/3
Estonian: HCV RNA genotüüp Genotüüp 2/3
English: • if you have liver problems.
Estonian: • kui teil esinevad maksaprobleemid.
English: • and the 2 hours after you take Revolade you don't consume any of the following:
Estonian: • ja 2 tundi pärast Revolade võtmist te ei tarvita midagi järgnevalt loetletust:
English: • persistent for ≥4 weeks, or
Estonian: • püsib 4 nädalat või
English: (eltrombopag)
Estonian: (eltrombopaag)
English: Side effects with frequency not known Frequency cannot be estimated from the available data
Estonian: Teadmata esinemissagedusega kõrvaltoimed Esinemissagedust ei saa hinnata olemasolevate andmete alusel
English: Table 5 Efficacy results from TRA100773B
Estonian: Tabel 5 Efektiivsuse tulemused uuringust TRA100773B
English: • Prepare the suspension with water only.
Estonian: • Suspensioon valmistada ainult veega.
English: • IMPORTANT: Because some medicine will remain in the mixing bottle, complete the following steps.
Estonian: • TÄHTIS: Osa ravimit võib jääda segamispudelisse, seetõttu tuleb läbi teha järgmised punktid.
English: However a risk for humans cannot be ruled out (see section 5.3).
Estonian: Sellegipoolest ei saa riski inimesele välistada (vt lõik 5.3).
English: Your doctor may consider it necessary to monitor your heart during treatment with Revolade and carry out an electrocardiogram (ECG) test.
Estonian: Teie arst võib pidada vajalikuks jälgida teie südant ravi ajal Revoladega ja kaaluda elektrokardiogrammi (EKG) tegemist.
English: • Administer the oral suspension immediately after preparation.
Estonian: • Suukaudne suspensioon manustada kohe pärast valmistamist.
English: • if you have another blood condition, such as myelodysplastic syndrome (MDS).
Estonian: • kui teil on mõni teine verehaigus, nt müelodüsplastiline sündroom (MDS).
English: If possible show them the pack, or this leaflet.
Estonian: Võimalusel näidake neile ravimi pakendit või käesolevat infolehte.
English: But there will still be some left in the bottle, even though you may not be able to see it.
Estonian: Osa ravimit on endiselt pudelis, isegi kui seda ei näe.
English: • Wash your hands with soap and water.
Estonian: • Peske käed seebi ja veega.
English: What you need to know before you take Revolade
Estonian: Mida on vaja teada enne Revolade võtmist
English: Make sure the child has time to swallow.
Estonian: Veenduge, et lapsel on aega ravim alla neelata.
English: IMPORTANT:
Estonian: TÄHTIS:
English: Your doctor will review the medicines you are taking, and suggest suitable replacements if necessary.
Estonian: Arst vaatab üle teie poolt kasutatavad ravimid ja soovitab vajadusel sobivaid asendusravimeid.
English: Effects were less severe at lower doses and were characterised by a spectrum of regenerative changes.
Estonian: Toime oli vähem tõsine väiksemate annuste puhul ning seda iseloomustasid erinevad regeneratiivsed muutused.
English: This was measured by delayed phototoxic index.
Estonian: Seda mõõdeti hilise fototoksilisuse indeksi abil.
English: You have now given the child nearly all of their dose of medicine.
Estonian: Nüüd on lapsele manustatud peaaegu kogu ravimiannus.
English: If this happens, wash the area immediately with soap and water.
Estonian: Kui see juhtub, peske seda ala otsekohe seebi ja veega.
English: p-value a
Estonian: p-väärtus a
English: If treatment is considered clinically indicated, close monitoring of these patients is required.
Estonian: Kui ravi on kliiniliselt näidustatud, on vajalik nende patsientide hoolikas jälgimine.
English: • 1 clean glass or cup filled with drinking water (not supplied)
Estonian: • 1 puhas klaas või tass joogiveega (ei ole komplektis)
English: Do not take more than one dose of Revolade in one day.
Estonian: Ärge võtke päevas üle ühe Revolade annuse.
English: Gently and slowly shake the mixing bottle backwards and forwards for at least 20 seconds to mix the water with the powder.
Estonian: Kergelt ja aeglasesti loksutage segamispudelit edasi-tagasi vähemalt 20 sekundit, et pulber ja vesi seguneksid.
English: A decision must be made whether to discontinue breast-feeding or to continue/abstain from Revolade therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Estonian: Tuleb teha otsus, kas lõpetada rinnaga toitmine või jätkata / loobuda ravist Revoladega, võttes arvesse rinnaga toitmisest saadavat kasu lapsele ja ravist saadavat kasu naisele.
English: Don't use Revolade if you are pregnant unless your doctor specifically recommends it.
Estonian: Ärge kasutage Revoladet, kui olete rase, välja arvatud juhul, kui arst seda spetsiaalselt soovitab.
English: • if you are allergic to eltrombopag or any of the other ingredients of this medicine (listed in section 6 under ‘What Revolade contains').
Estonian: • kui olete eltrombopaagi või selle ravimi mis tahes koostisosade (loetletud lõigus 6 „Mida Revolade sisaldab“) suhtes allergiline.
English: If you have MDS and take Revolade, your MDS may get worse.
Estonian: Kui teil on MDS ja te võtate Revoladet, võib teie seisund halveneda.
English: Component of a multipack, can't be sold separately.
Estonian: Multipakendi komponent, mitte müüa eraldi.
English: What Revolade is and what it is used for What you need to know before you take Revolade How to take Revolade
Estonian: Mis ravim on Revolade ja milleks seda kasutatakse Mida on vaja teada enne Revolade võtmist Kuidas Revoladet võtta
English: • accompanied by increased direct bilirubin, or
Estonian: • kaasneb direktse bilirubiini tõus või
English: Eltrombopag is highly bound to human plasma proteins (>99.9%), predominantly to albumin.
Estonian: Eltrombopaag seondub suurel määral inimese plasmavalkudega (>99,9%), peamiselt albumiiniga.
English: ITP study population
Estonian: ITP uuringu populatsioon
English: Table 4 Secondary efficacy results from RAISE
Estonian: Tabel 4 Uuringu RAISE teisesed efektiivsuse tulemused
English: • lack of interest, mood changes
Estonian: • huvipuudus, meeleolu muutused
English: Increase of alanine aminotransferase and aspartate aminotransferase may occur simultaneously, although at a lower frequency.
Estonian: Alaniinaminotransferaasi ja aspartaataminotransferaasi aktiivsuse suurenemine võivad esineda üheaegselt, kuigi väiksema esinemissagedusega.
English: The clinical significance of these QTc prolongation events is unknown.
Estonian: Nende QTc pikenemiste kliiniline tähtsus ei ole teada.
English: • some medicines to treat HIV infection, such as lopinavir and/or ritonavir
Estonian: • mõned ravimid, mida kasutatakse HIV infektsiooni raviks, nt lopinaviir ja/või ritonaviir
English: Revolade is not recommended for use in children under the age of one year with ITP due to insufficient data on safety and efficacy.
Estonian: Revoladet ei ole soovitatav kasutada ITP-ga lastel vanuses alla 1 aasta, kuna puuduvad piisavad andmed ohutuse ja efektiivsuse kohta.
English: Many people with hepatitis C have low platelet counts, not only as a result of the disease, but also due to some of the antiviral medicines that are used to treat it.
Estonian: Paljudel C-hepatiidiga inimestel võib olla vereliistakute arv madal mitte ainult haiguse tõttu, vaid ka mõnedest viirusevastastest ravimitest, mida selle viiruse raviks kasutatakse.
English: Albumin levels f
Estonian: Albumiini tasemed f
English: • ciclosporin used in the context of transplantations or immune diseases
Estonian: • tsüklosporiin, mida kasutatakse siirdamiste või immuunsüsteemi haiguste korral
English: In the clinical studies of eltrombopag, overall no clinically significant differences in safety of eltrombopag were observed between patients aged at least 65 years and younger patients.
Estonian: Eltrombopaagi kliinilistes uuringutes ei täheldatud üldiselt ravimi ohutuse kliiniliselt olulisi erinevusi vähemalt 65-aastaste ja nooremate patsientide vahel.
English: No specific temporal relationship between start of treatment and event of TEE were observed.
Estonian: Mingit spetsiifilist ajalist seost ravi alustamise ja TEE juhu vahel ei täheldatud.
English: Patients did not receive direct acting antiviral agents.
Estonian: Patsiendid ei saanud otseselt toimivaid antiviraalseid aineid.
English: Avoid direct contact with the medicine.
Estonian: Vältida otsest kokkupuudet ravimiga.
English: Safety pharmacology and repeat-dose toxicity
Estonian: Ohutusfarmakoloogia ja korduva annuse toksilisus
English: (The mixing bottle may become stained from the medicine.
Estonian: (Segamispudel võib määrduda ravimiga kokkupuutumisel.
English: Discard suspension if not administered within 30 minutes after preparation.
Estonian: Suspensioon hävitada, kui seda ei manustatud 30 minuti jooksul pärast valmistamist.
English: Do not open the foil sachets until ready for use.
Estonian: Ärge avage fooliumist kotikest enne, kui olete selle kasutamiseks valmis.
English: OATP1B1 and BCRP substrates
Estonian: OATP1B1 ja BCRP substraadid
English: Older people (65 years and above)
Estonian: Eakad (üle 65-aastased)
English: Do not take Revolade with dairy foods or drinks as the calcium in dairy products affects the absorption of the medicine.
Estonian: Ärge võtke Revoladet koos piimatoodetega, sest piimatoodetes sisalduv kaltsium mõjutab ravimi imendumist.
English: The remaining 5 patients discontinued treatment, three due to relapse at the month 3 extension visit.
Estonian: Ülejäänud 5 patsienti katkestasid ravi, nendest kolm tüsistumise tõttu 3. kuu jätku-uuringu visiidil.
English: If you stop taking Revolade
Estonian: Kui te lõpetate Revolade võtmise
English: The majority of patients (84%) had received at least 2 prior immunosuppressive therapies.
Estonian: Enamik patsiente (84%) oli eelnevalt saanud 2 immunospressiivset ravi.
English: Progression of existing myelodysplastic syndrome (MDS)
Estonian: Olemasolevate müelodüsplastiliste sündroomide (MDS) progresseerumine
English: • Take care that the child does not play with the bottle, cap, lid or syringes - there is a risk of choking if the child puts them in their mouth.
Estonian: • Vaadake hoolikalt, et laps ei mängiks pudeli, selle korgi, kaane ega süstaldega - nende sattumisel suhu võib laps lämbuda.